Changyou Zhan

Prof. Dr. Changyou Zhan


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZZZui Zhang
Zui Zhang
JGJuan Guan
Juan Guan
ZJZhuxuan Jiang
Zhuxuan Jiang
YYYang Yang
Yang Yang
JLJican Liu
Jican Liu
CZChangyou Zhan
Changyou Zhan
Protein corona presents a major obstacle to bench-to-bedside translation of targeted drug delivery systems, severely affecting targeting yields and directing unfavorable biodistribution. Corona-mediated targeting provides a new impetus for specific drug delivery by precisely manipulating interaction modes of functional plasma proteins on nano-surface. Here bio-inspired liposomes (SP-sLip) were developed by modifying liposomal surface with a short nontoxic peptide derived from Aβ1-42 that specifically interacts with the lipid-binding domain of exchangeable apolipoproteins. SP-sLip absorb plasma apolipoproteins A1, E and J, consequently exposing receptor-binding domain of apolipoproteins to achieve brain-targeted delivery. Doxorubicin loaded SP-sLip (SP-sLip/DOX) show significant enhancement of brain distribution and anti-brain cancer effect in comparison to doxorubicin loaded plain liposomes. SP-sLip preserve functions of the absorbed human plasma ApoE, and the corona-mediated targeting strategy works in SP modified PLGA nanoparticles. The present study may pave a new avenue to facilitate clinical translation of targeted drug delivery systems.

18 January 2019 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
ZJZhuxuan Jiang
Zhuxuan Jiang
JGJuan Guan
Juan Guan
JQJun Qian
Jun Qian
CZChangyou Zhan
Changyou Zhan
Targeted drug delivery is emerging as a promising strategy to achieve better clinical outcomes. Actively targeted drug delivery that utilizes overexpressed receptors or antigens on diseased tissues is receiving increasing scrutiny, especially due to the uncertainty of existence of the enhanced permeability and retention (EPR) effect in cancer patients. Peptide ligands are advantageous over other classes of targeting ligands due to their accessibility of high-throughput screening, ease of synthesis, high specificity and affinity, etc. In this review, we briefly summarize the resources of peptide ligands and discuss the pitfalls and perspectives of peptide ligand-mediated targeted delivery of nanomedicines.

30 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJuan Guan
Juan Guan
QSQing Shen
Qing Shen
ZZZui Zhang
Zui Zhang
ZJZhuxuan Jiang
Zhuxuan Jiang
YYYang Yang
Yang Yang
CZChangyou Zhan
Changyou Zhan
Targeting ligands are anticipated to facilitate the precise delivery of therapeutic agents to diseased tissues; however, they may also severely affect the interaction of nanocarriers with plasma proteins. Here, we study the immunocompatibility of brain-targeted liposomes, which inversely correlates with absorbed natural IgM. Modification of long, stable positively charged peptide ligands on liposomes is inclined to absorb natural IgM, leading to rapid clearance and enhanced immunogenicity. Small peptidomimetic D8 developed by computer-aided peptide design exhibits improved immunocompatibility by attenuating natural IgM absorption. The present study highlights the effects of peptide ligands on the formed protein corona and in vivo fate of liposomes. Stable positively charged peptide ligands play double-edged roles in targeted delivery, preserving in vivo bioactivities for binding receptors and long-term unfavorable interactions with the innate immune system. The development of D8 provides insights into how to rationally design immunocompatible drug delivery systems by modulating the protein corona composition.

21 October 2020 in ACS Nano
Verified
Journal Article
Closed access
HWHuan Wang
Huan Wang
TDTianhao Ding
Tianhao Ding
JGJuan Guan
Juan Guan
XLXia Liu
Xia Liu
JWJing Wang
Jing Wang
CZChangyou Zhan
Changyou Zhan

20 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KJKuan Jiang
Kuan Jiang
KTKaisong Tian
Kaisong Tian
YYYifei Yu
Yifei Yu
EWErcan Wu
Ercan Wu
MYMin Yang
Min Yang
CZChangyou Zhan
Changyou Zhan
Intrahepatic accumulation dominates organ distribution for most nanomedicines. However, obscure intrahepatic fate largely hampers regulation on their in vivo performance. Herein, PEGylated liposomal doxorubicin is exploited to clarify the intrahepatic fate of both liposomes and the payload in male mice. Kupffer cells initiate and dominate intrahepatic capture of liposomal doxorubicin, following to deliver released doxorubicin to hepatocytes with zonated distribution along the lobule porto-central axis. Increasing Kupffer cells capture promotes doxorubicin accumulation in hepatocytes, revealing the Kupffer cells capture-payload release-hepatocytes accumulation scheme. In contrast, free doxorubicin is overlooked by Kupffer cells, instead quickly distributing into hepatocytes by directly crossing fenestrated liver sinusoid endothelium. Compared to free doxorubicin, liposomal doxorubicin exhibits sustained metabolism/excretion due to the extra capture-release process. This work unveils the pivotal role of Kupffer cells in intrahepatic traffic of PEGylated liposomal therapeutics, and quantitively describes the intrahepatic transport/distribution/elimination process, providing crucial information for guiding further development of nanomedicines.

1 February 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZZZui Zhang
Zui Zhang
YCYuxiu Chu
Yuxiu Chu
CLCheng Li
Cheng Li
WTWenjing Tang
Wenjing Tang
JQJun Qian
Jun Qian
CZChangyou Zhan
Changyou Zhan